BioGaia AB (publ) (BIOG-B.ST)
SEK 110.5
(0.82%)
SEK 110.5
(0.82%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 2.33 Billion SEK | 5.39% |
| 2022 | 2.21 Billion SEK | 4.04% |
| 2021 | 2.12 Billion SEK | 11.23% |
| 2020 | 1.91 Billion SEK | 187.32% |
| 2019 | 665.9 Million SEK | 0.9% |
| 2018 | 659.97 Million SEK | 14.56% |
| 2017 | 576.11 Million SEK | 17.82% |
| 2016 | 488.97 Million SEK | 3.34% |
| 2015 | 473.17 Million SEK | 13.85% |
| 2014 | 415.6 Million SEK | 8.4% |
| 2013 | 383.41 Million SEK | -25.84% |
| 2012 | 517.02 Million SEK | 84.76% |
| 2011 | 279.83 Million SEK | 22.83% |
| 2010 | 227.82 Million SEK | 26.7% |
| 2009 | 179.81 Million SEK | 16.53% |
| 2008 | 154.3 Million SEK | 39.3% |
| 2007 | 110.77 Million SEK | 22.05% |
| 2006 | 90.76 Million SEK | 4.14% |
| 2005 | 87.15 Million SEK | -19.68% |
| 2004 | 108.5 Million SEK | -20.16% |
| 2003 | 135.9 Million SEK | -15.92% |
| 2002 | 161.63 Million SEK | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q3 | 1.9 Billion SEK | 0.22% |
| 2024 Q1 | 2.47 Billion SEK | 6.29% |
| 2024 Q2 | 1.9 Billion SEK | -23.36% |
| 2023 FY | 2.33 Billion SEK | 5.39% |
| 2023 Q4 | 2.33 Billion SEK | 1.26% |
| 2023 Q1 | 2.32 Billion SEK | 4.97% |
| 2023 Q3 | 2.3 Billion SEK | 6.82% |
| 2023 Q2 | 2.15 Billion SEK | -7.18% |
| 2022 Q3 | 2.16 Billion SEK | 3.78% |
| 2022 Q4 | 2.21 Billion SEK | 2.43% |
| 2022 FY | 2.21 Billion SEK | 4.04% |
| 2022 Q1 | 2.23 Billion SEK | 4.8% |
| 2022 Q2 | 2.08 Billion SEK | -6.61% |
| 2021 Q1 | 1.94 Billion SEK | 1.72% |
| 2021 FY | 2.12 Billion SEK | 11.23% |
| 2021 Q2 | 1.93 Billion SEK | -0.53% |
| 2021 Q4 | 2.12 Billion SEK | 8.15% |
| 2021 Q3 | 1.96 Billion SEK | 1.64% |
| 2020 Q3 | 711.86 Million SEK | 0.22% |
| 2020 Q2 | 710.28 Million SEK | -0.99% |
| 2020 Q4 | 1.91 Billion SEK | 168.77% |
| 2020 Q1 | 717.4 Million SEK | 7.73% |
| 2020 FY | 1.91 Billion SEK | 187.32% |
| 2019 Q1 | 705.58 Million SEK | 6.91% |
| 2019 FY | 665.9 Million SEK | 0.9% |
| 2019 Q4 | 665.9 Million SEK | 4.26% |
| 2019 Q3 | 638.67 Million SEK | 7.06% |
| 2019 Q2 | 596.57 Million SEK | -15.45% |
| 2018 Q4 | 659.97 Million SEK | 10.35% |
| 2018 Q1 | 625.12 Million SEK | 8.51% |
| 2018 Q2 | 591.13 Million SEK | -5.44% |
| 2018 Q3 | 598.09 Million SEK | 1.18% |
| 2018 FY | 659.97 Million SEK | 14.56% |
| 2017 Q2 | 479.46 Million SEK | -14.95% |
| 2017 FY | 576.11 Million SEK | 17.82% |
| 2017 Q4 | 576.11 Million SEK | 10.19% |
| 2017 Q3 | 522.83 Million SEK | 9.04% |
| 2017 Q1 | 563.75 Million SEK | 15.29% |
| 2016 Q4 | 488.97 Million SEK | 8.34% |
| 2016 FY | 488.97 Million SEK | 3.34% |
| 2016 Q3 | 451.32 Million SEK | 9.49% |
| 2016 Q2 | 412.21 Million SEK | -8.77% |
| 2016 Q1 | 451.82 Million SEK | -4.51% |
| 2015 Q4 | 473.17 Million SEK | 4.6% |
| 2015 Q2 | 442.08 Million SEK | -7.09% |
| 2015 Q3 | 452.35 Million SEK | 2.32% |
| 2015 FY | 473.17 Million SEK | 13.85% |
| 2015 Q1 | 475.79 Million SEK | 14.48% |
| 2014 FY | 415.6 Million SEK | 8.4% |
| 2014 Q2 | 396.06 Million SEK | -18.77% |
| 2014 Q3 | 388.95 Million SEK | -1.8% |
| 2014 Q4 | 415.6 Million SEK | 6.85% |
| 2014 Q1 | 487.58 Million SEK | 27.17% |
| 2013 FY | 383.41 Million SEK | -25.84% |
| 2013 Q1 | 537.61 Million SEK | 3.98% |
| 2013 Q4 | 383.41 Million SEK | 5.06% |
| 2013 Q3 | 364.93 Million SEK | -4.4% |
| 2013 Q2 | 381.72 Million SEK | -29.0% |
| 2012 Q1 | 641.69 Million SEK | 129.31% |
| 2012 Q2 | 542.57 Million SEK | -15.45% |
| 2012 Q4 | 517.02 Million SEK | -1.71% |
| 2012 Q3 | 525.99 Million SEK | -3.06% |
| 2012 FY | 517.02 Million SEK | 84.76% |
| 2011 FY | 279.83 Million SEK | 22.83% |
| 2011 Q2 | 236.25 Million SEK | -0.65% |
| 2011 Q1 | 237.79 Million SEK | 4.38% |
| 2011 Q4 | 279.83 Million SEK | 10.94% |
| 2011 Q3 | 252.24 Million SEK | 6.77% |
| 2010 Q2 | 196.38 Million SEK | -0.16% |
| 2010 Q3 | 211.94 Million SEK | 7.92% |
| 2010 FY | 227.82 Million SEK | 26.7% |
| 2010 Q4 | 227.82 Million SEK | 7.49% |
| 2010 Q1 | 196.69 Million SEK | 9.39% |
| 2009 FY | 179.81 Million SEK | 16.53% |
| 2009 Q4 | 179.81 Million SEK | 0.0% |
| 2009 Q2 | 165.33 Million SEK | 0.0% |
| 2008 FY | 154.3 Million SEK | 39.3% |
| 2007 FY | 110.77 Million SEK | 22.05% |
| 2006 FY | 90.76 Million SEK | 4.14% |
| 2005 FY | 87.15 Million SEK | -19.68% |
| 2004 FY | 108.5 Million SEK | -20.16% |
| 2003 FY | 135.9 Million SEK | -15.92% |
| 2002 FY | 161.63 Million SEK | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| AcuCort AB | 58.5 Million SEK | -3887.88% |
| AlzeCure Pharma AB (publ) | 32 Million SEK | -7190.988% |
| Enzymatica AB (publ) | 125.91 Million SEK | -1753.046% |
| Enorama Pharma AB (publ) | 34.38 Million SEK | -6685.485% |
| Gabather AB (publ) | 2.93 Million SEK | -79341.233% |
| Klaria Pharma Holding AB (publ.) | 73.12 Million SEK | -3090.904% |
| Moberg Pharma AB (publ) | 634.73 Million SEK | -267.586% |
| Nanexa AB (publ) | 132.25 Million SEK | -1664.133% |
| Newbury Pharmaceuticals AB (publ) | 90.87 Million SEK | -2467.584% |
| ODI Pharma AB | 12.27 Million SEK | -18907.659% |
| Orexo AB (publ) | 786.6 Million SEK | -196.617% |
| Probi AB (publ) | 1.55 Billion SEK | -50.49% |
| Swedencare AB (publ) | 9.52 Billion SEK | 75.497% |
| Swedish Orphan Biovitrum AB (publ) | 74.02 Billion SEK | 96.848% |
| Toleranzia AB | 160.42 Million SEK | -1354.362% |
| Vivesto AB | 355.87 Million SEK | -555.619% |